Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Israel · Delayed Price · Currency is ILS · Price in ILA

498.30

-16.20 (-3.15%)

At close: Mar 13, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Research and Development of Therapeutic Products	14.56M	9.50M	8.95M	14.70M	4.34M
Research and Development of Therapeutic Products Growth	53.24%	6.19%	-39.16%	238.70%	137.73%
Total	14.56M	9.50M	8.95M	14.70M	4.34M
Total Growth	53.24%	6.19%	-39.16%	238.70%	137.73%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	14.56M	9.50M	8.95M	14.70M	3.90M
United States Growth	53.24%	6.19%	-39.16%	277.48%	235.78%
Foreign	-	-	-	-	446.00K
Foreign Growth	-	-	-	-	-33.03%
Total	14.56M	9.50M	8.95M	14.70M	4.34M
Total Growth	53.24%	6.19%	-39.16%	238.70%	137.73%

Source: S&P Global Market Intelligence.